What is metolazone’s mechanism of action (MOA)?
Metolazone is a thiazide-like diuretic. It lowers blood pressure and increases urine output by blocking sodium reabsorption in the kidney’s distal tubule, which reduces sodium (and indirectly water) reabsorption and increases excretion. As a result, more sodium reaches downstream segments, where it promotes additional water loss through osmotic and ionic effects.
Where in the kidney does metolazone act?
Like thiazide diuretics, metolazone primarily acts in the distal convoluted tubule (DCT), inhibiting sodium transport there. This shifts fluid and electrolyte handling such that urine volume increases.
How does that translate to electrolyte changes?
Because metolazone changes sodium reabsorption in the DCT, it can also affect other ions handled downstream. Clinically, this can lead to electrolyte disturbances such as:
- Low potassium (hypokalemia)
- Low sodium (hyponatremia)
- Possible metabolic alkalosis
These are typical risks for diuretics that increase distal sodium delivery.
Why is metolazone often used in combination with other diuretics?
Metolazone is commonly used when loop diuretics alone are insufficient, especially in resistant edema. Its distal tubule effect can “add” to the natriuretic effect by targeting a different nephron segment, helping overcome diuretic resistance where sodium still gets reabsorbed further downstream.
What should patients watch for?
Patients are commonly advised to monitor for symptoms related to volume depletion and electrolyte shifts, such as dizziness, weakness, muscle cramps, or signs of dehydration, and to follow prescribed lab monitoring for electrolytes and kidney function.
Sources
No sources were provided in the prompt to cite.